Browse the detailed record of transactions filed by Michel Cognet, Supervisory Board Chairman. Insider active across 1 companies, notably Altur Investissement. In total, 2 disclosures have been published. Total volume traded: €373k. The latest transaction was disclosed on 27 January 2023 (Cession). Regulator: AMF. All data is openly available.
2 of 2 declarations
Michel Cognet is a French executive with deep experience in private equity governance and the oversight of both listed and unlisted companies. He serves as Chairman of the Supervisory Board of ALTUR INVESTISSEMENT, a role to which he was co-opted in June 2014 and formally appointed in July 2014. In that capacity, he contributes to the company’s strategic supervision, investment discipline and governance framework, within a platform that operates through direct investments, co-investments, fund-of-funds and sponsored funds. His career is closely associated with board-level oversight, financial control and investment governance. Company filings also identify him as manager of JNMC Consulting Sarl and president of Renaissance Corporate, indicating an advisory profile focused on corporate structuring, investment matters and executive support. Over time, he has held a range of mandates across the investment ecosystem, including positions linked to Turenne Capital Partenaires, Turenne Holding, Turenne Participations, RFAS 3 and RFAS 4, as well as board or supervisory roles in companies such as BIOBank, Acropole, Dromadaire, Solem, Ubicast, Belledone Développement, Demunich, Azulis Capital and Innov8 Group. At ALTUR INVESTISSEMENT, Michel Cognet plays a central role in a governance model built around careful portfolio monitoring, capital allocation discipline and adherence to sound internal controls. The company’s reports also highlight his involvement on the Audit Committee, underscoring his contribution to financial transparency, risk oversight and performance monitoring. The group has pursued a focused investment strategy in specialized sectors, particularly healthcare, with direct holdings such as Menix, BIOBank, Cousin Surgery and Naogen Pharma. His expertise sits at the intersection of finance, governance and corporate development. His value lies in supporting growth companies, helping secure investment decisions and framing long-term value creation. He is therefore strongly associated with the stability of ALTUR INVESTISSEMENT’s governance and with a professional, structured approach to private equity management.